These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 29506672)

  • 1. MicroRNA-Based Drugs for Brain Tumors.
    Anthiya S; Griveau A; Loussouarn C; Baril P; Garnett M; Issartel JP; Garcion E
    Trends Cancer; 2018 Mar; 4(3):222-238. PubMed ID: 29506672
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current progress for the use of miRNAs in glioblastoma treatment.
    Tivnan A; McDonald KL
    Mol Neurobiol; 2013 Dec; 48(3):757-68. PubMed ID: 23625340
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MiRNA-21 silencing mediated by tumor-targeted nanoparticles combined with sunitinib: A new multimodal gene therapy approach for glioblastoma.
    Costa PM; Cardoso AL; Custódia C; Cunha P; Pereira de Almeida L; Pedroso de Lima MC
    J Control Release; 2015 Jun; 207():31-9. PubMed ID: 25861727
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current Challenges and Opportunities in Treating Glioblastoma.
    Shergalis A; Bankhead A; Luesakul U; Muangsin N; Neamati N
    Pharmacol Rev; 2018 Jul; 70(3):412-445. PubMed ID: 29669750
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-throughput screening uncovers miRNAs enhancing glioblastoma cell susceptibility to tyrosine kinase inhibitors.
    Cunha PP; Costa PM; Morais CM; Lopes IR; Cardoso AM; Cardoso AL; Mano M; Jurado AS; Pedroso de Lima MC
    Hum Mol Genet; 2017 Nov; 26(22):4375-4387. PubMed ID: 28973155
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nanoparticles: Novel vehicles in treatment of Glioblastoma.
    Pourgholi F; Hajivalili M; Farhad JN; Kafil HS; Yousefi M
    Biomed Pharmacother; 2016 Feb; 77():98-107. PubMed ID: 26796272
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug delivery approaches for the treatment of glioblastoma multiforme.
    Fakhoury M
    Artif Cells Nanomed Biotechnol; 2016 Sep; 44(6):1365-73. PubMed ID: 26046399
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MicroRNA based theranostics for brain cancer: basic principles.
    Petrescu GED; Sabo AA; Torsin LI; Calin GA; Dragomir MP
    J Exp Clin Cancer Res; 2019 May; 38(1):231. PubMed ID: 31142339
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Strategies to improve delivery of anticancer drugs across the blood-brain barrier to treat glioblastoma.
    Oberoi RK; Parrish KE; Sio TT; Mittapalli RK; Elmquist WF; Sarkaria JN
    Neuro Oncol; 2016 Jan; 18(1):27-36. PubMed ID: 26359209
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting strategies on miRNA-21 and PDCD4 for glioblastoma.
    Wang G; Wang JJ; Tang HM; To SS
    Arch Biochem Biophys; 2015 Aug; 580():64-74. PubMed ID: 26142886
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular Targets and Nanoparticulate Systems Designed for the Improved Therapeutic Intervention in Glioblastoma Multiforme.
    Akhter MH; Rizwanullah M; Ahmad J; Amin S; Ahmad MZ; Minhaj MA; Mujtaba MA; Ali J
    Drug Res (Stuttg); 2021 Mar; 71(3):122-137. PubMed ID: 33167048
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MiR-203 downregulation is responsible for chemoresistance in human glioblastoma by promoting epithelial-mesenchymal transition via SNAI2.
    Liao H; Bai Y; Qiu S; Zheng L; Huang L; Liu T; Wang X; Liu Y; Xu N; Yan X; Guo H
    Oncotarget; 2015 Apr; 6(11):8914-28. PubMed ID: 25871397
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular characterizations of glioblastoma, targeted therapy, and clinical results to date.
    Bastien JI; McNeill KA; Fine HA
    Cancer; 2015 Feb; 121(4):502-16. PubMed ID: 25250735
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anticancer drug candidate CBL0137, which inhibits histone chaperone FACT, is efficacious in preclinical orthotopic models of temozolomide-responsive and -resistant glioblastoma.
    Barone TA; Burkhart CA; Safina A; Haderski G; Gurova KV; Purmal AA; Gudkov AV; Plunkett RJ
    Neuro Oncol; 2017 Feb; 19(2):186-196. PubMed ID: 27370399
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intratumoral heterogeneity: pathways to treatment resistance and relapse in human glioblastoma.
    Qazi MA; Vora P; Venugopal C; Sidhu SS; Moffat J; Swanton C; Singh SK
    Ann Oncol; 2017 Jul; 28(7):1448-1456. PubMed ID: 28407030
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activation of KATP channels increases anticancer drug delivery to brain tumors and survival.
    Ningaraj NS; Sankpal UT; Khaitan D; Meister EA; Vats T
    Eur J Pharmacol; 2009 Jan; 602(2-3):188-93. PubMed ID: 19027730
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MicroRNAs in glioblastoma pathogenesis and therapy: A comprehensive review.
    Ahir BK; Ozer H; Engelhard HH; Lakka SS
    Crit Rev Oncol Hematol; 2017 Dec; 120():22-33. PubMed ID: 29198335
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overcoming the blood-brain tumor barrier for effective glioblastoma treatment.
    van Tellingen O; Yetkin-Arik B; de Gooijer MC; Wesseling P; Wurdinger T; de Vries HE
    Drug Resist Updat; 2015 Mar; 19():1-12. PubMed ID: 25791797
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of Myc and let-7a in glioblastoma, glucose metabolism and response to therapy.
    Wang G; Wang J; Zhao H; Wang J; Tony To SS
    Arch Biochem Biophys; 2015 Aug; 580():84-92. PubMed ID: 26151775
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MicroRNA-based therapy for glioblastoma: Opportunities and challenges.
    Lei Q; Yang Y; Zhou W; Liu W; Li Y; Qi N; Li Q; Wen Z; Ding L; Huang X; Li Y; Wu J
    Eur J Pharmacol; 2023 Jan; 938():175388. PubMed ID: 36403686
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.